These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32877039)

  • 21. Vaccinating against HPV: A Call to Action.
    Poh A
    Cancer Discov; 2016 Mar; 6(3):222-3. PubMed ID: 26842650
    [No Abstract]   [Full Text] [Related]  

  • 22. HPV vaccines: what remains to be done? Interview by Lauren Constable.
    Zur Hausen H
    Expert Rev Vaccines; 2011 Nov; 10(11):1505-7. PubMed ID: 22043949
    [No Abstract]   [Full Text] [Related]  

  • 23. Association of Human Papillomavirus Vaccination With the Incidence of Squamous Cell Carcinomas of the Anus in the US.
    Berenson AB; Guo F; Chang M
    JAMA Oncol; 2022 Apr; 8(4):1-3. PubMed ID: 35142803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus vaccine.
    Suba EJ; Raab SS;
    N Engl J Med; 2007 Sep; 357(11):1155; author reply 1155-6. PubMed ID: 17874469
    [No Abstract]   [Full Text] [Related]  

  • 25. Cervical cancer: the second-generation vaccines move forward.
    Tuma RS
    J Natl Cancer Inst; 2009 Jun; 101(11):774-5. PubMed ID: 19470948
    [No Abstract]   [Full Text] [Related]  

  • 26. Reducing the burden of cervical cancer and HPV-related diseases through vaccination. Introduction.
    Cox JT
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s3-4. PubMed ID: 16520682
    [No Abstract]   [Full Text] [Related]  

  • 27. Human papillomavirus vaccine--opportunity and challenge.
    Baden LR; Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2007 May; 356(19):1990-1. PubMed ID: 17494932
    [No Abstract]   [Full Text] [Related]  

  • 28. [Efficacy and safety of vaccines against human papillomavirus (HPV)].
    Prygiel M; Janaszek-Seydlitz W
    Przegl Epidemiol; 2012; 66(4):657-65. PubMed ID: 23484396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary and secondary prevention of cervical cancer--opportunities and challenges.
    Markowitz LE; Unger ER; Saraiya M
    J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary strategies for HPV infection and cervical cancer prevention.
    Harper DM; Demars LR
    Clin Obstet Gynecol; 2014 Jun; 57(2):256-78. PubMed ID: 24686336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].
    Lazcano-Ponce E; Salmerón-Castro J; García-Carrancá A; Aranda-Flores C; Madrid-Marina V; Gómez-Altamirano CM; Martínez-Montañez OG
    Salud Publica Mex; 2009; 51(4):336-41. PubMed ID: 19668929
    [No Abstract]   [Full Text] [Related]  

  • 32. HPV vaccine: a cornerstone of female health.
    Temte JL
    Am Fam Physician; 2007 Jan; 75(1):28, 30. PubMed ID: 17225700
    [No Abstract]   [Full Text] [Related]  

  • 33. The new era of cervical cancer prevention: HPV vaccination.
    Monk BJ; Herzog TJ
    Gynecol Oncol; 2008 May; 109(2 Suppl):S1-3. PubMed ID: 18482553
    [No Abstract]   [Full Text] [Related]  

  • 34. Cervical cancers after human papillomavirus vaccination.
    Beller U; Abu-Rustum NR
    Obstet Gynecol; 2009 Feb; 113(2 Pt 2):550-552. PubMed ID: 19155953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real world effectiveness of population-based roll out of human papillomavirus vaccination against rates of genital warts.
    Smith JS; Weiderpass E
    J Natl Cancer Inst; 2013 Apr; 105(7):449-51. PubMed ID: 23486549
    [No Abstract]   [Full Text] [Related]  

  • 36. No Vacillation on HPV Vaccination.
    Sipp D; Frazer IH; Rasko JEJ
    Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low affordability may limit the effect of cervical cancer vaccination in central and eastern European countries.
    Zubor P; Danko J; Kajo K; Szunyogh N
    J Clin Oncol; 2007 Dec; 25(34):5534-7. PubMed ID: 18048836
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mandating HPV vaccination: what are the arguments?
    Smith CM
    J Christ Nurs; 2008; 25(2):74-80; quiz 81-2. PubMed ID: 18401926
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.